Pfizer and GSK: Assessing Dividend Sustainability Amid Patent Cliffs
Pfizer yields 6.3% and GSK yields 4.1%, and both companies face significant patent expirations before 2030. Pfizer's dividend used 89% of its free cash flow in the twelve months to June 2026, while GSK's payout ratio was 39%. Pfizer's CEO has said the dividend will be maintained, and GSK raised its dividend 18% in fiscal 2025 after previously cutting it; GSK's net debt reached £22 billion following the Nuvalent acquisition.
Pfizer’s 6.3% payout relies on cash generation that has tightened: dividends absorbed 89% of free cash flow in the year to June 2026. The company expects new and acquired medicines to grow while COVID revenue declines, and management projects cost savings through 2029. Patent expirations before 2028 add pressure, though the CEO has pledged to keep the dividend.
GSK yields 4.1% and faces dolutegravir exclusivity loss between 2028 and 2030. Its payout ratio was 39%, and it lifted the fiscal 2025 dividend 18% after an earlier reduction. Net debt reached £22 billion following the Nuvalent deal, adding interest costs. Sales and core EPS grew in Q2 2026.
If Pfizer or GSK trim payouts, income-focused investors, including retirees, could feel reduced cash flow. Patent cliffs may influence drug pricing, generic competition, and research spending, potentially affecting patients’ access to medicines. GSK’s higher debt could constrain investment or acquisitions. However, both firms currently signal dividend continuity, so broad societal effects may remain limited unless cash flows deteriorate.